Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
2025 Q4 -tulosraportti

Äänite tulossa

2 päivää sitten

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
10 000--
2 280--
3 000--
1--
100--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 2 t sitten
    ·
    2 t sitten
    ·
    A thought. If those who bought shares for 250 million in April have agreed that they cannot be resold for the first 6 months, doesn't this mean that the company cannot be sold in its entirety before November 2026?
    1 t sitten · Muokattu
    ·
    1 t sitten · Muokattu
    ·
    I believe those conditions for the sale of the share issue, shares applied only to insiders and the company.
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    There are manger who believe that Circio is 'close to' being acquired, just as it happened for Orna and Orbital. But nothing could probably be more wrong, if one looks at where the 2 companies were when they were acquired compared to where Circio is today. I have made an overview that comparisons the most important parameters for the 3 companies. https://drive.google.com/file/d/1bjOfeV3mMUHFcoXQu45cZe2EgKLK5mFK/view?usp=sharing The picture speaks for itself, and once again I want to highlight CAR-T data (for the PoC, which comes in Q2) as the first real data point that will tell us if we will get a platform or not, which will truly decide the case. Agreed, there can certainly be positive signals, expectations and narratives from the CEO about 'the share price can 10-double again' and other fairy tale narratives. But not without data, that can supports that the promises can be delivered on. It is also why management says that it will take 12-24 months before Circio is truly ready to be acquisition. It is fine that the share price calms down a bit again and the share price can be driven by data and facts, instead of hype and expectations (that cannot be met) Judge for yourself if you think that Circio is ready to becomes acquired 'shortly'...? DATA is King - we need to see it!
    2 t sitten
    ·
    2 t sitten
    ·
    Is it perhaps about one to 2 years? Has orbital been acquired?
    1 t sitten · Muokattu
    ·
    1 t sitten · Muokattu
    ·
    Yes, in October '25 by Bristol Myers Squibb....Who paid approx. $1.5 billion (~15–16 mrd NOK) for the asset. ...And this was Preclinical...
  • 2 t sitten
    ·
    2 t sitten
    ·
    Difficult to understand this drop. Partnerships, Karolinska which has tested circRNA on human skin that worked, Boston in May, and these are just the things we know about so far.
    1 t sitten
    ·
    1 t sitten
    ·
    I mean, that's roughly correct, yes.
  • 2 t sitten
    ·
    2 t sitten
    ·
    Correct me if I'm wrong. Competing companies have come a bit further in the research on a product that is not close to the functionality of Circvec. When they during this year see that Circio has the right technology they actually must have, it will either be a bidding war for Circio or all stakeholders will buy the technology under license. The ingenious thing here is that Circio has not patented the technology but keeps it secret so that they can profit from it forever. Had they patented it, all information about the technology would have been released after 10 years. Others have tried to copy it, most recently a company in Asia that didn't succeed. The reason may be that Circio has the world's foremost researcher in this field in its company who has several thousand publications.
    2 t sitten
    ·
    2 t sitten
    ·
    Yes, that is my thought too. This is a piggy bank that can become many piggy banks.
  • 2 t sitten
    ·
    2 t sitten
    ·
    There are some players who have specialized in shorting companies like Circio. We all remember the Ultimovacs case from 2 years ago.
    2 t sitten
    ·
    2 t sitten
    ·
    But Circio is groundbreaking technology that should be valued at a premium
    2 t sitten
    ·
    2 t sitten
    ·
    Absolutely, that's why it's so frustrating with everything that has happened, Correction, RSI, shorting, panic selling fear, allegedly overpriced,++ One thing leads to another, you also see people hyping like madmen. But there's a bottom somewhere, whether it's 3-4 or 5. Then it calms down. What happens after that will be exciting. A shame about all the chaos, people are selling and losing money on something that can become really big. It could be bought out within one and a half years for God knows how much. The way I perceive it, it's groundbreaking and almost unavoidable that this won't become big. But I'm not a biotech guy, just trying to learn, read up and understand.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Äänite tulossa

2 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 2 t sitten
    ·
    2 t sitten
    ·
    A thought. If those who bought shares for 250 million in April have agreed that they cannot be resold for the first 6 months, doesn't this mean that the company cannot be sold in its entirety before November 2026?
    1 t sitten · Muokattu
    ·
    1 t sitten · Muokattu
    ·
    I believe those conditions for the sale of the share issue, shares applied only to insiders and the company.
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    There are manger who believe that Circio is 'close to' being acquired, just as it happened for Orna and Orbital. But nothing could probably be more wrong, if one looks at where the 2 companies were when they were acquired compared to where Circio is today. I have made an overview that comparisons the most important parameters for the 3 companies. https://drive.google.com/file/d/1bjOfeV3mMUHFcoXQu45cZe2EgKLK5mFK/view?usp=sharing The picture speaks for itself, and once again I want to highlight CAR-T data (for the PoC, which comes in Q2) as the first real data point that will tell us if we will get a platform or not, which will truly decide the case. Agreed, there can certainly be positive signals, expectations and narratives from the CEO about 'the share price can 10-double again' and other fairy tale narratives. But not without data, that can supports that the promises can be delivered on. It is also why management says that it will take 12-24 months before Circio is truly ready to be acquisition. It is fine that the share price calms down a bit again and the share price can be driven by data and facts, instead of hype and expectations (that cannot be met) Judge for yourself if you think that Circio is ready to becomes acquired 'shortly'...? DATA is King - we need to see it!
    2 t sitten
    ·
    2 t sitten
    ·
    Is it perhaps about one to 2 years? Has orbital been acquired?
    1 t sitten · Muokattu
    ·
    1 t sitten · Muokattu
    ·
    Yes, in October '25 by Bristol Myers Squibb....Who paid approx. $1.5 billion (~15–16 mrd NOK) for the asset. ...And this was Preclinical...
  • 2 t sitten
    ·
    2 t sitten
    ·
    Difficult to understand this drop. Partnerships, Karolinska which has tested circRNA on human skin that worked, Boston in May, and these are just the things we know about so far.
    1 t sitten
    ·
    1 t sitten
    ·
    I mean, that's roughly correct, yes.
  • 2 t sitten
    ·
    2 t sitten
    ·
    Correct me if I'm wrong. Competing companies have come a bit further in the research on a product that is not close to the functionality of Circvec. When they during this year see that Circio has the right technology they actually must have, it will either be a bidding war for Circio or all stakeholders will buy the technology under license. The ingenious thing here is that Circio has not patented the technology but keeps it secret so that they can profit from it forever. Had they patented it, all information about the technology would have been released after 10 years. Others have tried to copy it, most recently a company in Asia that didn't succeed. The reason may be that Circio has the world's foremost researcher in this field in its company who has several thousand publications.
    2 t sitten
    ·
    2 t sitten
    ·
    Yes, that is my thought too. This is a piggy bank that can become many piggy banks.
  • 2 t sitten
    ·
    2 t sitten
    ·
    There are some players who have specialized in shorting companies like Circio. We all remember the Ultimovacs case from 2 years ago.
    2 t sitten
    ·
    2 t sitten
    ·
    But Circio is groundbreaking technology that should be valued at a premium
    2 t sitten
    ·
    2 t sitten
    ·
    Absolutely, that's why it's so frustrating with everything that has happened, Correction, RSI, shorting, panic selling fear, allegedly overpriced,++ One thing leads to another, you also see people hyping like madmen. But there's a bottom somewhere, whether it's 3-4 or 5. Then it calms down. What happens after that will be exciting. A shame about all the chaos, people are selling and losing money on something that can become really big. It could be bought out within one and a half years for God knows how much. The way I perceive it, it's groundbreaking and almost unavoidable that this won't become big. But I'm not a biotech guy, just trying to learn, read up and understand.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
10 000--
2 280--
3 000--
1--
100--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Äänite tulossa

2 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 2 t sitten
    ·
    2 t sitten
    ·
    A thought. If those who bought shares for 250 million in April have agreed that they cannot be resold for the first 6 months, doesn't this mean that the company cannot be sold in its entirety before November 2026?
    1 t sitten · Muokattu
    ·
    1 t sitten · Muokattu
    ·
    I believe those conditions for the sale of the share issue, shares applied only to insiders and the company.
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    There are manger who believe that Circio is 'close to' being acquired, just as it happened for Orna and Orbital. But nothing could probably be more wrong, if one looks at where the 2 companies were when they were acquired compared to where Circio is today. I have made an overview that comparisons the most important parameters for the 3 companies. https://drive.google.com/file/d/1bjOfeV3mMUHFcoXQu45cZe2EgKLK5mFK/view?usp=sharing The picture speaks for itself, and once again I want to highlight CAR-T data (for the PoC, which comes in Q2) as the first real data point that will tell us if we will get a platform or not, which will truly decide the case. Agreed, there can certainly be positive signals, expectations and narratives from the CEO about 'the share price can 10-double again' and other fairy tale narratives. But not without data, that can supports that the promises can be delivered on. It is also why management says that it will take 12-24 months before Circio is truly ready to be acquisition. It is fine that the share price calms down a bit again and the share price can be driven by data and facts, instead of hype and expectations (that cannot be met) Judge for yourself if you think that Circio is ready to becomes acquired 'shortly'...? DATA is King - we need to see it!
    2 t sitten
    ·
    2 t sitten
    ·
    Is it perhaps about one to 2 years? Has orbital been acquired?
    1 t sitten · Muokattu
    ·
    1 t sitten · Muokattu
    ·
    Yes, in October '25 by Bristol Myers Squibb....Who paid approx. $1.5 billion (~15–16 mrd NOK) for the asset. ...And this was Preclinical...
  • 2 t sitten
    ·
    2 t sitten
    ·
    Difficult to understand this drop. Partnerships, Karolinska which has tested circRNA on human skin that worked, Boston in May, and these are just the things we know about so far.
    1 t sitten
    ·
    1 t sitten
    ·
    I mean, that's roughly correct, yes.
  • 2 t sitten
    ·
    2 t sitten
    ·
    Correct me if I'm wrong. Competing companies have come a bit further in the research on a product that is not close to the functionality of Circvec. When they during this year see that Circio has the right technology they actually must have, it will either be a bidding war for Circio or all stakeholders will buy the technology under license. The ingenious thing here is that Circio has not patented the technology but keeps it secret so that they can profit from it forever. Had they patented it, all information about the technology would have been released after 10 years. Others have tried to copy it, most recently a company in Asia that didn't succeed. The reason may be that Circio has the world's foremost researcher in this field in its company who has several thousand publications.
    2 t sitten
    ·
    2 t sitten
    ·
    Yes, that is my thought too. This is a piggy bank that can become many piggy banks.
  • 2 t sitten
    ·
    2 t sitten
    ·
    There are some players who have specialized in shorting companies like Circio. We all remember the Ultimovacs case from 2 years ago.
    2 t sitten
    ·
    2 t sitten
    ·
    But Circio is groundbreaking technology that should be valued at a premium
    2 t sitten
    ·
    2 t sitten
    ·
    Absolutely, that's why it's so frustrating with everything that has happened, Correction, RSI, shorting, panic selling fear, allegedly overpriced,++ One thing leads to another, you also see people hyping like madmen. But there's a bottom somewhere, whether it's 3-4 or 5. Then it calms down. What happens after that will be exciting. A shame about all the chaos, people are selling and losing money on something that can become really big. It could be bought out within one and a half years for God knows how much. The way I perceive it, it's groundbreaking and almost unavoidable that this won't become big. But I'm not a biotech guy, just trying to learn, read up and understand.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
10 000--
2 280--
3 000--
1--
100--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt
© 2026 Nordnet Bank AB.
Nordnet | Alvar Aallon katu 5 C, 3. krs | FI-00100 Helsinki